The vascular endothelial growth factor receptor-2 (VEGFR-2) is also called as kinase insert domain containing receptor (KDR). There are seven immunoglobulin-like (Ig-like) domains at the extracellular region (EC) of VEGFR-2. This gene is mapped to human chromosome 4q12.
Immunogen
The antiserum was produced against synthesized peptide derived from human VEGFR2 around the phosphorylation site of Tyr1175.
Immunogen Range: 1141-1190
Application
Anti-phospho-VEGFR2 (pTyr1175) antibody has been used in immunoblotting.
Biochem/physiol Actions
The immunoglobulin-like (Ig-like) domains of the vascular endothelial growth factor receptor-2 (VEGFR-2) are essential for specific ligand binding and receptor dimerization. It helps to activate multiple signaling cascades. VEGF-KDR participates in angiogenesis. VEGFR2 is involved in progression of several cancers like gliomas, malignant peripheral nerve sheath tumors, triple-negative breast cancer (TNBC) and gastrointestinal stromal tumors (GISTs).
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Atherosclerotic-arterial occlusions decrease tissue perfusion causing ischemia to lower limbs in patients with peripheral arterial disease (PAD). Ischemia in muscle induces an angiogenic response, but the magnitude of this response is frequently inadequate to meet tissue perfusion requirements. Alternate splicing
Immunoglobulin-like domain 4-mediated ligand-independent dimerization triggers VEGFR-2 activation in HUVECs and VEGFR2-positive breast cancer cells.
Zhang S, et al.
Breast Cancer Research and Treatment, 163(3), 423-434 (2017)
Vascular endothelial growth factor receptor-2 polymorphisms have protective effect against the development of tendinopathy in volleyball athletes.
Salles JI, et al.
PLoS ONE, 11(12), e0167717-e0167717 (2016)
The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.